Literature DB >> 950465

C3 requirements for formation of alternative pathway C5 convertase.

M R Daha, D T Fearon, K F Austen.   

Abstract

Although alternative pathway C3 and C5 convertases both have active proteolytic sites dependent on the same protein, Bb, the quantitative requirements for the expression of these activities are sufficiently different to permit their delineation in terms of B input an cell-bound C3b. That the labile component of each active site is Bb was established by their parallel decay rates, regeneration of the original specificities with B in the presence of D, and stabilization of each convertase by C3NeF. The evidence that the spatial relationships of Bb and C3b on the cell surface for C3 and C5 convertase activities are distinct is based not only upon the decay and regeneration of each original convertase but more so upon their interconversion. C3 convertase is converted to C5 convertase by interaction with additional C3 whereas C5 convertase reverts to a C3 convertase by treatment with C3 INA. The capacity of C3 INA treatment to abolish C5 convertase sites without affecting C3 convertase sites indicates the existence of two functional species of C3b, one of which is protected in the C3bBb complex whereas the other is exposed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 950465

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Convertase inhibitory properties of Staphylococcal extracellular complement-binding protein.

Authors:  Ilse Jongerius; Brandon L Garcia; Brian V Geisbrecht; Jos A G van Strijp; Suzan H M Rooijakkers
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

2.  Regulation of C5 convertase activity by properdin, factors B and H.

Authors:  J M Weiler
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

3.  Structural basis for therapeutic inhibition of complement C5.

Authors:  Matthijs M Jore; Steven Johnson; Devon Sheppard; Natalie M Barber; Yang I Li; Miles A Nunn; Hans Elmlund; Susan M Lea
Journal:  Nat Struct Mol Biol       Date:  2016-03-28       Impact factor: 15.369

4.  Stabilization of homologous and heterologous cell-bound amplification convertases, C3bBb, by C3 nephritic factor.

Authors:  M R Daha; L A Van Es
Journal:  Immunology       Date:  1981-05       Impact factor: 7.397

5.  "Immune complexes" in every cutaneous vasculitis with "immune deposits"?

Authors:  F Weidner
Journal:  Arch Dermatol Res       Date:  1979-02-23       Impact factor: 3.017

6.  Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.

Authors:  C W Vogel; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

7.  Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.

Authors:  A Nicholson-Weller; J P March; S I Rosenfeld; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

8.  Effects of antibiotic resistance plasmids on the bactericidal activity of normal rabbit serum.

Authors:  A M Reynard; M E Beck; R K Cunningham
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

9.  Activated C3 (C3b) in the nephritic glomerulus.

Authors:  C Pan; C F Strife; A J McAdams; C D West
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

10.  The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.

Authors:  H Kitamura; M Tsuboi; K Nagaki
Journal:  Immunology       Date:  1986-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.